NASDAQ:OCX OncoCyte - OCX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding OncoCyte Co. Please log in to your account or sign up in order to add this asset to your watchlist. $0.38 -0.01 (-3.30%) (As of 02/3/2023 10:46 AM ET) Add Compare Share Share Today's Range$0.37▼$0.3950-Day Range$0.25▼$0.5052-Week Range$0.24▼$1.75Volume87,872 shsAverage Volume196,147 shsMarket Capitalization$44.51 millionP/E RatioN/ADividend YieldN/APrice Target$1.35 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media OncoCyte MarketRank™ ForecastAnalyst RatingHold2.25 Rating ScoreUpside/Downside247.5% Upside$1.35 Price TargetShort InterestHealthy1.19% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$7,000 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($0.38) to ($0.43) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.29 out of 5 starsMedical Sector260th out of 1,029 stocksDiagnostic Substances Industry4th out of 15 stocks 3.1 Analyst's Opinion Consensus RatingOncoCyte has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 buy rating, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $1.35, OncoCyte has a forecasted upside of 247.5% from its current price of $0.39.Amount of Analyst CoverageOncoCyte has only been the subject of 3 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.19% of the outstanding shares of OncoCyte have been sold short.Short Interest Ratio / Days to CoverOncoCyte has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in OncoCyte has recently decreased by 16.57%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldOncoCyte does not currently pay a dividend.Dividend GrowthOncoCyte does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for OCX. Previous Next 1.6 News and Social Media Coverage News SentimentOncoCyte has a news sentiment score of -0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for OncoCyte this week, compared to 2 articles on an average week.MarketBeat Follows2 people have added OncoCyte to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, OncoCyte insiders have bought more of their company's stock than they have sold. Specifically, they have bought $7,000.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 4.06% of the stock of OncoCyte is held by insiders.Percentage Held by Institutions81.20% of the stock of OncoCyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for OncoCyte are expected to decrease in the coming year, from ($0.38) to ($0.43) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of OncoCyte is -0.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of OncoCyte is -0.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOncoCyte has a P/B Ratio of 0.55. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About OncoCyte (NASDAQ:OCX) StockOncoCyte Corp. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. Its products include DetermaRx and DetermaIO. The firm also offers pharmaceutical services like multi-analyte test development and clinical trial services. The company was founded in September 2009 and is headquartered in Alameda, CA.Read More Receive OCX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OncoCyte and its competitors with MarketBeat's FREE daily newsletter. Email Address OCX Stock News HeadlinesJanuary 30, 2023 | americanbankingnews.comOncoCyte Co. (NASDAQ:OCX) Sees Significant Drop in Short InterestDecember 17, 2022 | markets.businessinsider.comOncocyte To Slash Over 40% Staff, Eliminate COO, CSO Roles; To Sell 70% Stake In Razor GenomicsFebruary 3, 2023 | Investing Trends (Ad)Elon Musk Claims Solar Will Soon Power the WorldThe world's wealthiest person -- Elon Musk -- is a visionary investor. And he fully expects solar power to be our #1 energy source within a few decades. Utility-scale solar is already becoming the cheapest option for electricity generation globally. So with the push toward clean, renewable energy, it's no wonder solar is also becoming one of the fastest growing sectors in the U.S. stock market.December 17, 2022 | seekingalpha.comOncocyte cuts 40% of staff; to sell 70% stake in subsidiaryDecember 16, 2022 | finance.yahoo.comOncocyte Announces Initiatives to Focus Corporate StrategyNovember 30, 2022 | finance.yahoo.comOncocyte Announces Executive Leadership ChangesNovember 30, 2022 | finance.yahoo.comOncocyte Announces the Appointment of Louis E. Silverman as a Member of Its Board of DirectorsNovember 18, 2022 | finance.yahoo.comOncoCyte (OCX) Upgraded to Buy: What Does It Mean for the Stock?February 3, 2023 | PressReach (Ad)Biotech Stock AlertRead Small Pharma's depression clinical trial results.November 12, 2022 | finanznachrichten.deOncocyte Corporation: Oncocyte Reports Third Quarter 2022 Financial ResultsNovember 12, 2022 | seekingalpha.comOncoCyte Corporation (OCX) Q3 2022 Earnings Call TranscriptNovember 12, 2022 | finance.yahoo.comOncoCyte (OCX) Reports Q3 Loss, Misses Revenue EstimatesNovember 10, 2022 | finance.yahoo.comOncocyte Reports Third Quarter 2022 Financial ResultsOctober 27, 2022 | finance.yahoo.comOncocyte to Announce Third Quarter 2022 Financial ResultsOctober 26, 2022 | seekingalpha.comOncoCyte: FDA's Regulatory Arm Might Pressure This MicrocapOctober 19, 2022 | nasdaq.comWill OncoCyte (NASDAQ:OCX) Spend Its Cash Wisely? - NasdaqOctober 18, 2022 | seekingalpha.comCareDx: Shaking Off First-Mover Disadvantage (NASDAQ:CDNA) - Seeking AlphaOctober 16, 2022 | finance.yahoo.comWe're Keeping An Eye On OncoCyte's (NASDAQ:OCX) Cash Burn RateOctober 9, 2022 | ca.finance.yahoo.comOncoCyte Corporation (OCX)October 6, 2022 | finance.yahoo.comDetermaIO™ Clinical Test to be used in SWOG Cancer Research Network Biomarker Study for Breast CancerOctober 6, 2022 | globenewswire.comDetermaIO™ Clinical Test to be used in SWOG Cancer Research Network Biomarker Study for Breast Cancer - GlobeNewswireOctober 3, 2022 | reuters.comOCX.N - OncoCyte Corp | Stock Price & Latest News | ReutersSeptember 26, 2022 | finance.yahoo.comOncoCyte (OCX) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?September 23, 2022 | nasdaq.comStrength Seen in Cano Health, Inc. (CANO): Can Its 32.2% Jump Turn into More Strength? - NasdaqSeptember 15, 2022 | reuters.comOCX.A - OncoCyte Corp | Stock Price & Latest News | ReutersSeptember 7, 2022 | globenewswire.comOncocyte Announces Unanimous Recommendation from the Advisory Panel for Clinical Diagnostic Laboratory Tests on DetermaRx to CMS - GlobeNewswireSeptember 7, 2022 | finance.yahoo.comOncocyte Announces Unanimous Recommendation from the Advisory Panel for Clinical Diagnostic Laboratory Tests on DetermaRx to CMSSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive OCX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OncoCyte and its competitors with MarketBeat's FREE daily newsletter. Email Address OCX Company Calendar Last Earnings11/10/2022Today2/03/2023Next Earnings (Estimated)3/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Diagnostic substances Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:OCX CUSIPN/A CIK1642380 Weboncocyte.com Phone(949) 409-7600Fax510-521-3389EmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Forecast$1.35 High Stock Price Forecast$3.00 Low Stock Price Forecast$0.50 Forecasted Upside/Downside+259.8%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-64,100,000.00 Net Margins-787.97% Pretax Margin-786.76% Return on Equity-54.99% Return on Assets-24.47% Debt Debt-to-Equity RatioN/A Current Ratio2.83 Quick Ratio2.83 Sales & Book Value Annual Sales$7.73 million Price / Sales5.76 Cash FlowN/A Price / Cash FlowN/A Book Value$0.71 per share Price / Book0.53Miscellaneous Outstanding Shares118,640,000Free Float113,827,000Market Cap$44.51 million OptionableOptionable Beta1.73 Key ExecutivesJoshua RiggsChief Executive OfficerAnish JohnChief Financial Officer & Senior Vice PresidentEkkehard SchützChief Technology OfficerMitchell Stuart LevineCorporate Development OfficerPadma SundarChief Commercial OfficerKey CompetitorsImmuCellNASDAQ:ICCCTrinity BiotechNASDAQ:TRIBBiomericaNASDAQ:BMRANymox PharmaceuticalNASDAQ:NYMXAspira Women's HealthNASDAQ:AWHView All CompetitorsInsiders & InstitutionsPenbrook Management LLCSold 355,675 shares on 1/24/2023Ownership: 0.175%Defender Capital LLC.Sold 279,050 shares on 1/12/2023Ownership: 1.916%Alfred D KingsleyBought 25,000 shares on 12/22/2022Total: $7,000.00 ($0.28/share)Balyasny Asset Management LLCBought 42,091 shares on 11/16/2022Ownership: 0.045%BlackRock Inc.Sold 38,095 shares on 11/15/2022Ownership: 1.943%View All Insider TransactionsView All Institutional Transactions OCX Stock - Frequently Asked Questions Should I buy or sell OncoCyte stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OncoCyte in the last twelve months. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" OCX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OCX, but not buy additional shares or sell existing shares. View OCX analyst ratings or view top-rated stocks. What is OncoCyte's stock price forecast for 2023? 4 brokers have issued 12-month price objectives for OncoCyte's stock. Their OCX share price forecasts range from $0.50 to $3.00. On average, they expect the company's share price to reach $1.35 in the next year. This suggests a possible upside of 255.3% from the stock's current price. View analysts price targets for OCX or view top-rated stocks among Wall Street analysts. How have OCX shares performed in 2023? OncoCyte's stock was trading at $0.3209 at the start of the year. Since then, OCX shares have increased by 18.4% and is now trading at $0.38. View the best growth stocks for 2023 here. Are investors shorting OncoCyte? OncoCyte saw a decline in short interest in January. As of January 15th, there was short interest totaling 1,410,000 shares, a decline of 16.6% from the December 31st total of 1,690,000 shares. Based on an average trading volume of 414,300 shares, the short-interest ratio is presently 3.4 days. View OncoCyte's Short Interest. When is OncoCyte's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 9th 2023. View our OCX earnings forecast. How were OncoCyte's earnings last quarter? OncoCyte Co. (NASDAQ:OCX) issued its earnings results on Thursday, November, 10th. The company reported ($0.08) EPS for the quarter, topping analysts' consensus estimates of ($0.13) by $0.05. The business had revenue of $1.02 million for the quarter, compared to the consensus estimate of $1.50 million. OncoCyte had a negative net margin of 787.97% and a negative trailing twelve-month return on equity of 54.99%. What other stocks do shareholders of OncoCyte own? Based on aggregate information from My MarketBeat watchlists, some companies that other OncoCyte investors own include VBI Vaccines (VBIV), Biocept (BIOC), Aurora Cannabis (ACB), CymaBay Therapeutics (CBAY), Fulcrum Therapeutics (FULC), Xeris Biopharma (XERS), Zynerba Pharmaceuticals (ZYNE), AbbVie (ABBV), Acasti Pharma (ACST) and Aileron Therapeutics (ALRN). What is OncoCyte's stock symbol? OncoCyte trades on the NASDAQ under the ticker symbol "OCX." Who are OncoCyte's major shareholders? OncoCyte's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Defender Capital LLC. (1.92%), Penbrook Management LLC (0.18%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Albert P Parker, Alfred D Kingsley, Andrew J Last, Broadwood Partners, LP, Cavan M Redmond, Douglas T Ross, Gisela Paulsen, Li Yu, Mitchell S Levine, Pura Vida Investments, Llc and Ronald Asbury Andrews. View institutional ownership trends. How do I buy shares of OncoCyte? Shares of OCX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is OncoCyte's stock price today? One share of OCX stock can currently be purchased for approximately $0.38. How much money does OncoCyte make? OncoCyte (NASDAQ:OCX) has a market capitalization of $45.08 million and generates $7.73 million in revenue each year. The company earns $-64,100,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis. How can I contact OncoCyte? OncoCyte's mailing address is 15 CUSHING, IRVINE CA, 92618. The official website for the company is oncocyte.com. The company can be reached via phone at (949) 409-7600, via email at bob@lifesciadvisors.com, or via fax at 510-521-3389. This page (NASDAQ:OCX) was last updated on 2/3/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.